Camurus: Positive CAM2056 Phase I Topline - Redeye
Redeye sees the phase I results from the controlled study of semaglutide monthly depot as a success, paving the way for future studies with CAM2056 and boding well for the Eli Lilly collaboration.
ANNONS
Redeye sees the phase I results from the controlled study of semaglutide monthly depot as a success, paving the way for future studies with CAM2056 and boding well for the Eli Lilly collaboration.
